ReviewAmerican journal of clinical and experimental urology2025
Dual role of autophagy in bone metastasis: mechanistic insights and therapeutic targeting.
Review in American journal of clinical and experimental urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Emerging research themes in drug resistance in osteosarcoma: a 25-year bibliometric and visualized analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Therapeutic Effects of the Most Common Polyphenols Found inNutrients · 2026Review
- Mechanistic Insights into Autophagy-Dependent Cell Death (ADCD): A Novel Avenue for Cancer Therapy.Cells · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autophagy, a cellular degradation mechanism, plays a dual role in the progression and therapy of bone metastases in cancers, including prostate cancer. This review delves into the intricate roles of autophagy in both tumor suppression and progression, with a focus on its impact on bone metastasis and osteosarcoma (OS). Initially, autophagy acts as a tumor suppressor by eliminating damaged organelles and proteins, thus preventing tumor initiation. However, as cancer progresses, autophagy supports cancer cell survival under stress conditions, such as nutrient deprivation and hypoxia, and contributes to drug resistance. Specifically, in bone metastasis from breast and prostate cancers, autophagy facilitates tumor cell migration, invasion, and survival. The review also highlights the therapeutic potential of targeting autophagy in cancer treatment, especially in overcoming drug resistance in osteosarcoma, where autophagy modulation could reduce chemoresistance. By understanding the dual roles of autophagy in cancer and bone metastasis, new therapeutic strategies can be developed to target this process, offering hope for improved treatment outcomes in cancers prone to bone metastasis, including prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.